Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2016 | Aug. 09, 2016 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2016 | |
Document Fiscal Year Focus | 2,016 | |
Document Fiscal Period Focus | Q2 | |
Trading Symbol | ZIOP | |
Entity Registrant Name | ZIOPHARM ONCOLOGY INC | |
Entity Central Index Key | 1,107,421 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 131,732,423 |
BALANCE SHEETS
BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2016 | Dec. 31, 2015 |
Current assets: | ||
Cash and cash equivalents | $ 109,004 | $ 140,717 |
Receivables, net of allowance | 15 | 446 |
Prepaid expenses and other current assets | 17,690 | 11,358 |
Total current assets | 126,709 | 152,521 |
Property and equipment, net | 682 | 581 |
Deposits | 128 | 128 |
Other non-current assets | 493 | 494 |
Total assets | 128,012 | 153,724 |
Current liabilities: | ||
Accounts payable | 2,031 | 2,008 |
Accrued expenses | 7,392 | 8,906 |
Deferred rent - current portion | 223 | 348 |
Deferred revenue - current portion | 6,389 | 6,861 |
Total current liabilities | 16,035 | 18,123 |
Deferred rent, net of current portion | 200 | 313 |
Deferred revenue, net of current portion | 44,722 | 47,917 |
Series 1 preferred stock issuance obligation | 119,045 | |
Total liabilities | 180,002 | 66,353 |
Commitments and contingencies (Note 5) | ||
Stockholders' equity (deficit): | ||
Preferred stock, $0.001 par value; 30,000,000 shares authorized, 250,000 designated as Series 1 preferred stock, no shares issued and outstanding | ||
Common stock, $0.001 par value; 250,000,000 shares authorized; 131,732,423 and 131,718,579 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively | 132 | 132 |
Additional paid-in capital - common stock | 583,797 | 579,939 |
Accumulated deficit | (635,919) | (492,700) |
Total stockholders' equity (deficit) | (51,990) | 87,371 |
Total liabilities and stockholders' equity (deficit) | $ 128,012 | $ 153,724 |
BALANCE SHEETS (Parenthetical)
BALANCE SHEETS (Parenthetical) - $ / shares | Jun. 30, 2016 | Dec. 31, 2015 |
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 30,000,000 | 30,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 250,000,000 | 250,000,000 |
Common stock, shares issued | 131,732,423 | 131,718,579 |
Common stock, shares outstanding | 131,732,423 | 131,718,579 |
Series 1 Preferred Stock | ||
Preferred stock, shares authorized | 250,000 | 250,000 |
STATEMENTS OF OPERATIONS
STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | |
Collaboration revenue | $ 1,697 | $ 272 | $ 3,666 | $ 544 |
Operating expenses: | ||||
Research and development, including costs of contracts | 129,228 | 7,424 | 139,427 | 81,673 |
General and administrative | 3,711 | 7,073 | 7,521 | 11,323 |
Total operating expenses | 132,939 | 14,497 | 146,948 | 92,996 |
Loss from operations | (131,242) | (14,225) | (143,282) | (92,452) |
Other income (expense), net | 42 | 14 | 63 | 10 |
Net loss | $ (131,200) | $ (14,211) | $ (143,219) | $ (92,442) |
Net loss per share - basic and diluted | $ (1.01) | $ (0.11) | $ (1.10) | $ (0.76) |
Weighted average common shares outstanding used to compute net loss per share - basic and diluted | 130,385,077 | 128,413,417 | 130,271,806 | 120,953,279 |
STATEMENT OF STOCKHOLDERS' EQUI
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - 6 months ended Jun. 30, 2016 - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital Common Stock | Accumulated Deficit |
Beginning Balance (in shares) at Dec. 31, 2015 | 131,718,579 | |||
Beginning Balance at Dec. 31, 2015 | $ 87,371 | $ 132 | $ 579,939 | $ (492,700) |
Stock-based compensation | $ 4,075 | 4,075 | ||
Exercise of employee stock options (in shares) | 169,000 | 137,346 | ||
Exercise of employee stock options | $ 551 | $ 1 | 550 | |
Repurchase of common stock (in shares) | (168) | |||
Repurchase of common stock | (2) | (2) | ||
Restricted stock buy-back at vesting to cover taxes (in shares) | (123,334) | |||
Restricted stock buy-back at vesting to cover taxes | (853) | $ (1) | (852) | |
Issuance of common stock in a license agreement | 87 | 87 | ||
Net loss | (143,219) | (143,219) | ||
Ending Balance (in shares) at Jun. 30, 2016 | 131,732,423 | |||
Ending Balance at Jun. 30, 2016 | $ (51,990) | $ 132 | $ 583,797 | $ (635,919) |
STATEMENTS OF CASH FLOWS
STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | |
Cash flows from operating activities: | ||
Net loss | $ (143,219) | $ (92,442) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 155 | 236 |
Stock-based compensation | 4,075 | 4,577 |
Common stock issued in exchange for license agreement | 67,285 | |
Preferred stock obligation in exchange for license agreement | 119,045 | |
Issuance of common stock in a license agreement | 87 | |
Loss on disposal of fixed assets | (1) | |
(Increase) decrease in: | ||
Receivables | 431 | 55 |
Prepaid expenses and other current assets | (6,332) | (3,302) |
Other noncurrent assets | 1 | (18) |
Increase (decrease) in: | ||
Accounts payable | 23 | 1,138 |
Accrued expenses | (1,513) | 1,569 |
Deferred revenue | (3,666) | (544) |
Deferred rent | (239) | 19 |
Other noncurrent liabilities | 17 | |
Net cash used in operating activities | (31,152) | (21,411) |
Cash flows from investing activities: | ||
Purchases of property and equipment | (257) | (22) |
Net cash used in investing activities | (257) | (22) |
Cash flows from financing activities: | ||
Proceeds from exercise of stock options | 551 | 3,140 |
Repurchase of restricted common stock | (853) | (246) |
Repurchase of common stock | (2) | (34) |
Proceeds from issuance of common stock, net | 94,320 | |
Net cash provided by financing activities | (304) | 97,180 |
Net increase (decrease) in cash and cash equivalents | (31,713) | 75,747 |
Cash and cash equivalents, beginning of period | 140,717 | 42,803 |
Cash and cash equivalents, end of period | 109,004 | 118,550 |
Supplementary disclosure of cash flow information: | ||
Cash paid for interest | 0 | 0 |
Cash paid for income taxes | 0 | 0 |
Supplementary disclosure of noncash investing and financing activities: | ||
Issuance of common stock in license agreement | $ 67,285 | |
Series 1 preferred stock issuance obligation issued in a license agreement | $ 119,045 |
Business
Business | 6 Months Ended |
Jun. 30, 2016 | |
Business | 1. Business Overview ZIOPHARM Oncology, Inc., which is referred to herein as “ZIOPHARM” or the “Company,” is a biopharmaceutical company seeking to acquire, develop and commercialize, on its own or with partners, a diverse portfolio of cancer therapies that address unmet medical needs. The Company’s operations to date have consisted primarily of raising capital and conducting research and development. The Company’s fiscal year ends on December 31. The Company has operated at a loss since its inception in 2003 and has minimal revenues. The Company anticipates that its losses will continue for the foreseeable future. At June 30, 2016, the Company’s accumulated deficit was approximately $635.9 million. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing or to achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. There can be no assurance that any such financing can be obtained by the Company, or if obtained, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company’s working capital requirements until it achieves profitable operations. Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States have been condensed or omitted pursuant to such rules and regulations. It is management’s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2015, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed with the SEC on February 24, 2016, or the Form 10-K. The year-end balance sheet data was derived from the audited financial statements but does not include all disclosures required by generally accepted accounting principles in the United States. The results disclosed in the statements of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results to be expected for the full fiscal year. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. The Company’s most significant estimates and judgments used in the preparation of its financial statements are: • Clinical trial expenses; • Collaboration agreements; • Fair value measurements for stock-based compensation and Series 1 preferred stock; and • Income taxes. Subsequent Events The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. During this period, the Company did not have any material subsequent events that impacted its financial statements or disclosures. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2016 | |
Summary of Significant Accounting Policies | 2. Summary of Significant Accounting Policies The Company’s significant accounting policies were identified in the Company’s Form 10-K. There have been no material changes in those policies since the filing of its Form 10-K. |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2016 | |
Fair Value Measurements | 3. Fair Value Measurements The Company accounts for its financial assets and liabilities using fair value measurements. The authoritative accounting guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows: • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015 were as follows: ($ in thousands) Balance as Fair Value Measurements at Reporting Date Using Description Quoted Prices in Significant Significant Cash equivalents $ 106,074 $ 106,074 $ — $ — Series 1 preferred stock issuance obligation $ (119,045 ) $ — $ — $ (119,045 ) ($ in thousands) Balance as of Fair Value Measurements at Reporting Date Using Description Quoted Prices in Significant Significant Cash equivalents $ 137,405 $ 137,405 $ — $ — The cash equivalents represent deposits in a short term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. The Company’s Level 3 financial liabilities consist of the Series 1 preferred stock issuance obligation entered into in connection with the 2016 ECP Amendment and 2016 GvHD Amendment with Intrexon on June 29, 2016. The obligation to issue the preferred stock was valued using a probability-weighted approach and a Monte Carlo simulation model. See Note 5 for additional disclosures on the 2016 ECP and 2016 GvHD Amendments and Note 8 for additional disclosure on the rights and preferences of the Series 1 preferred stock and valuation methodology. |
Net Loss per Share
Net Loss per Share | 6 Months Ended |
Jun. 30, 2016 | |
Net Loss per Share | 4. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company’s potential dilutive shares, which include outstanding common stock options, unvested restricted stock and preferred stock, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potential shares of common stock at June 30, 2016 and 2015 consisted of the following: June 30, 2016 2015 Stock options 3,438,103 3,543,331 Unvested restricted common stock 1,236,388 1,123,517 4,674,491 4,666,848 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2016 | |
Commitments and Contingencies | 5. Commitments and Contingencies Operating Leases Prior to December 31, 2012, the Company entered into an operating lease in New York, NY for office space. In accordance with this agreement, the Company entered into a letter of credit in the amount of $388 thousand, naming the Company’s landlord as beneficiary. In January 2012, the Company amended the lease agreement, adding additional office space. The collateral for the letter of credit is restricted cash and recorded in other non-current assets on the balance sheet as of June 30, 2016 and December 31, 2015. The lease for office space in New York, NY expires in October 2018. On October 17, 2013, the Company entered into a sublease agreement to lease all of its New York office space to a subtenant. The Company remains primarily liable to pay rent on the original lease. The Company recorded a loss on the sublease in the amount of $729 thousand for the year ended December 31, 2013, representing the remaining contractual obligation of $2.3 million, less $1.6 million in payments from its subtenant. The Company retired assets as a result of this sublease with a net book value of $392 thousand, and recorded a loss on disposal of fixed assets for the same amount for the year ended December 31, 2013. The Company continues to maintain the $388 thousand letter of credit in respect of the New York office space included in other non-current assets. Prior to December 31, 2012, the Company entered into separate operating lease agreements for various spaces in a building in Boston, MA. In June 2012, the Company re-negotiated a master lease for the entire Boston office space that incorporated all three lease agreements under the same master agreement expiring in August 2016. On December 21, 2015 and April 15, 2016, we renewed the sublease for the Company’s corporate headquarters in Boston, MA through August 31, 2021. As of June 30, 2016 and December 31, 2015, a total security deposit of $128 thousand is included in deposits on the balance sheet. On August 30, 2013, the Company entered into a sublease agreement to lease a portion of its Boston office to a subtenant. The Company remains liable to pay rent on the original lease. The Company recorded a loss on the sublease in the amount of $42 thousand for the year ended December 31, 2013, representing the remaining contractual obligation of $367 thousand, less $325 thousand in payments from its subtenant. This sublease tenant vacated the leased premises in October 2014. At December 31, 2014, the Company applied the $20 thousand deposit received from the sublease tenant against its outstanding rent obligation. On March 31, 2015, the Company recorded a loss of $167 thousand on the first floor sublease. On May 22, 2015, the Company subleased the vacant office space for approximately $105 thousand for the period of June 2015 through August 2016, and the tenant provided a security deposit of $17 thousand. Since the prior lease obligation has been fully expensed, rent received from the tenant will reduce current rent expense. Total rent expense was approximately $122 thousand and $477 thousand for the six months ended June 30, 2016 and 2015, respectively. The Company records rent expense on a straight-line basis over the term of the lease. Accordingly, the Company has recorded a liability for deferred rent at June 30, 2016 and December 31, 2015 of $423 thousand ($223 thousand current and $200 thousand long-term) and $661 thousand ($348 thousand current and $313 thousand long-term), respectively, which is recorded in deferred rent on the balance sheets. License Agreements Exclusive Channel Partner Agreement with Intrexon Corporation for the Cancer Programs On January 6, 2011, the Company entered into an Exclusive Channel Partner Agreement, or the Channel Agreement, with Intrexon that governs a “channel partnering” arrangement in which the Company uses Intrexon’s technology to research, develop and commercialize products in which DNA is administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which the Company collectively refers to as the Cancer Program. This Channel Agreement establishes committees comprised of representatives of the Company and Intrexon that govern activities related to the Cancer Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property. The Channel Agreement grants the Company a worldwide license to use patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving DNA administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which is collectively referred to as the ZIOPHARM Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of ZIOPHARM Products, and otherwise is non-exclusive. Subject to limited exceptions, the Company may not sublicense these rights without Intrexon’s written consent. Under the Channel Agreement, and subject to certain exceptions, the Company is responsible for, among other things, the performance of the Cancer Program, including the development, commercialization and certain aspects of manufacturing of ZIOPHARM Products. Intrexon is responsible for establishing manufacturing capabilities and facilities for the bulk manufacture of products developed under the Cancer Program, certain other aspects of manufacturing and costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Intrexon’s patents. Prior to being amended pursuant to the Third Amendment to Exclusive Channel Partner Agreement, or the 2016 ECP Amendment, discussed below, and subject to certain expense allocations and other offsets provided in the Channel Agreement, the Company was obligated to pay Intrexon on a quarterly basis 50% of net profits derived in that quarter from the sale of ZIOPHARM Products, calculated on a ZIOPHARM Product-by- ZIOPHARM Product basis. The Company likewise agreed to pay Intrexon on a quarterly basis 50% of revenue obtained in that quarter from a sublicensor in the event of a sublicensing arrangement. In addition, in partial consideration for each party’s execution and delivery of the Channel Agreement, the Company entered into a stock purchase agreement with Intrexon. Upon termination of the Channel Agreement, the Company may continue to develop and commercialize any ZIOPHARM Product that, at the time of termination: • Is being commercialized by the Company; • Has received regulatory approval; • Is a subject of an application for regulatory approval that is pending before the applicable regulatory authority; or • Is the subject of at least an ongoing Phase 2 clinical trial (in the case of a termination by Intrexon due to an uncured breach or a voluntary termination by the Company), or an ongoing Phase 1 clinical trial in the field (in the case of a termination by the Company due to an uncured breach or a termination by Intrexon following an unconsented assignment by the Company or its election not to pursue development of a Superior Therapy (as defined in the Channel Agreement)). The Company’s obligation to pay 50% of net profits (now 20% of net profits after the amendment pursuant to the 2016 ECP Amendment, discussed below) or revenue described above with respect to these “retained” products will survive termination of the Channel Agreement. Exclusive Channel Collaboration Agreement with Intrexon Corporation for Graft-Versus-Host Disease (GvHD) On September 28, 2015, the Company, entered into the GvHD Agreement with Intrexon, whereby the Company will use Intrexon’s technology directed towards in vivo The exclusive collaboration, or the GvHD Program, will focus on the pursuit of the following engineered cell therapy strategies, used either separately or in combination, for the targeted treatment of GvHD: (i) the infusion of regulatory T cells expressing membrane-bound and/or soluble interleukin-2 and (ii) the deployment of orally delivered, genetically modified L. lactis The GvHD Agreement grants the Company a worldwide license to use specified patents and other intellectual property of Intrexon in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products developed under the GvHD Program, or the Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of the Products, and otherwise is non-exclusive. Subject to limited exceptions, the Company may not sublicense the rights described without Intrexon’s written consent. Under the GvHD Agreement, and subject to certain exceptions, the Company is responsible for, among other things, the performance of the GvHD Program including development, commercialization and certain aspects of manufacturing of the Products. Among other things, Intrexon is responsible for the costs of establishing manufacturing capabilities and facilities for the bulk manufacture of the Products, certain other aspects of manufacturing, costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Intrexon’s patents. The Company paid Intrexon a technology access fee of $10.0 million in cash in October 2015 and will reimburse Intrexon for all research and development costs. Subject to certain expense allocations and other offsets provided in the GvHD Agreement, the GvHD Agreement also provides for equal sharing of the profits derived from the sale of the Products. The Company has determined that the rights acquired in the GvHD Agreement represent in-process research and development with no alternative future use. Accordingly, the Company recorded a charge of $10.0 million to research and development expense in 2015. During the first 24 months after September 28, 2015, the GvHD Agreement may be terminated by (i) either party in the event of a material breach by the other, except for the failure of the other party to use diligent efforts or to comply with any diligence obligations set forth in the GvHD Agreement and (ii) Intrexon under certain circumstances if the Company assigns its rights under the GvHD Agreement without Intrexon’s consent. Following such twenty-four month period, Intrexon may also terminate the GvHD Agreement if the Company elects not to pursue the development of the GvHD Program identified by Intrexon that is a “Superior Therapy,” as such term is defined in the GvHD Agreement. Also following such period, the Company may voluntarily terminate the GvHD Agreement upon 90 days’ written notice to Intrexon. Upon termination of the GvHD Agreement, the Company may continue to develop and commercialize any Product that, at the time of termination: • is being commercialized by the Company, • has received regulatory approval, • is a subject of an application for regulatory approval that is pending before the applicable regulatory authority, or • is the subject of at least an ongoing Phase 2 clinical trial (in the case of a termination by Intrexon due to a Company uncured breach or a voluntary termination by the Company), or an ongoing Phase 1 clinical trial (in the case of a termination by the Company due to an Intrexon uncured breach or a termination by Intrexon following an unconsented assignment by the Company or the Company’s election not to pursue development of a Superior Therapy). The Company’s obligation to pay 50% of net profits or revenue with respect to these “retained” products will survive termination of the GvHD Agreement. Amendment of Collaborations with Intrexon On March 27, 2015, the Company and Intrexon entered into an Exclusive Channel Partner Amendment, or ECP Amendment, amending the Channel Agreement. The ECP Amendment modifies the scope of the parties’ collaboration under the Channel Agreement in connection with the Ares Trading Agreement discussed below. Pursuant to the ECP Amendment, the chimeric antigen receptor T cell products to be developed and commercialized pursuant to the Ares Trading Agreement shall be included within the Intrexon/ZIOPHARM collaboration under the Channel Agreement. The ECP Amendment provides that Intrexon will pay to the Company fifty percent of all payments Intrexon receives for upfronts, milestones and royalties under the Ares Trading Agreement. On June 29, 2016, the Company entered into (1) the 2016 ECP Amendment with Intrexon amending the Channel Agreement, and (2) an Amendment to Exclusive Channel Collaboration Agreement with Intrexon, which the Company refers to as the 2016 GvHD Amendment, amending the existing Exclusive Channel Collaboration Agreement with Intrexon, effective September 28, 2015, which the Company refers to as the GvHD Agreement. The 2016 ECP Amendment reduced the royalty percentage that the Company will pay to Intrexon under the Channel Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of ZIOPHARM Products, calculated on a ZIOPHARM Product-by-ZIOPHARM Product basis, subject to certain expense allocations and other offsets provided in the Channel Agreement. The 2016 GvHD Amendment reduced the royalty percentage that the Company will pay to Intrexon under the GvHD Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of Products (as defined in the GvHD Agreement), subject to certain expense allocations and other offsets provided in the GvHD Agreement. The reductions in the royalty percentages provided by the 2016 ECP Amendment and the 2016 GvHD Amendment do not apply to sublicensing revenue or royalties under the Channel Agreement and GvHD Agreement, nor do they apply to any royalties or other payments made with respect to sublicensing revenue from the Company’s existing collaboration with Merck Serono, the biopharmaceutical business of Merck KGaA. In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company agreed to issue to Intrexon 100,000 shares of its newly designated Series 1 Preferred Stock. Each share of the Company’s Series 1 Preferred Stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization, and certain other rights, preferences, privileges and obligations (See note 8). License Agreement—The University of Texas MD Anderson Cancer Center On January 13, 2015, the Company, together with Intrexon, entered into a License Agreement, or the MD Anderson License, with The University of Texas MD Anderson Cancer Center, or MD Anderson. Pursuant to the MD Anderson License, the Company and Intrexon hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells and T cell receptors, or TCR’s arising from the laboratory of Laurence Cooper, M.D., Ph.D., who became the Chief Executive Officer of the Company on May 7, 2015 and was formerly a tenured professor of pediatrics at MD Anderson and now currently a visiting scientist under that institution’s policies, as well as either co-exclusive or non-exclusive licenses under certain related technologies. Pursuant to the terms of the MD Anderson License, MD Anderson received consideration consisting of $50.0 million in shares of the Company’s common stock (or 10,124,561 shares), and $50.0 million in shares of Intrexon’s common stock, in each case based on a trailing 20 day volume weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the announcement of the entry into the MD Anderson License, collectively referred to as the License Shares, pursuant to the terms of the License Shares Securities Issuance Agreement described below. The License Shares were issued to MD Anderson on March 11, 2015 pursuant to the terms of the MD Anderson License. On January 9, 2015, in order to induce MD Anderson to enter into the MD Anderson License on an accelerated schedule, the Company and Intrexon entered into a letter agreement, or the Letter Agreement, pursuant to which MD Anderson received consideration of $7.5 million in shares of the Company’s common stock (or 1,597,602 shares), and $7.5 million in shares of Intrexon’s common stock, in each case based on a trailing 20 day volume weighted average of the closing price of the Company’s and Intrexon’s common stock ending on the date prior to the execution of the Letter Agreement, collectively referred to as the Incentive Shares, in the event that the MD Anderson License was entered into on or prior to 8:00 am Pacific Time on January 14, 2015. The Incentive Shares were issued to MD Anderson on March 11, 2015 pursuant to the terms of the Incentive Shares Securities Issuance Agreement described below. On August 17, 2015, the Company, Intrexon and MD Anderson entered into a research and development agreement, or the Research and Development Agreement, to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year. During the quarter ended June 30, 2016, the Company made one quarterly payment of $3.8 million and has paid an aggregate of $18.8 million under this arrangement. As of June 30, 2016, MD Anderson has used $1.7 million to offset costs incurred pursuant to the MD Anderson License and the Research and Development Agreement. The net balance of $17.1 million is included in other current assets at June 30, 2016. The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the License; provided, however, that following the expiration of the term of the MD Anderson License, the Company and Intrexon shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Intrexon are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third party contract if the Company and Intrexon are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Intrexon, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Intrexon and may be terminated by the mutual written agreement of the Company, Intrexon and MD Anderson. In connection with the License and the issuance of the License Shares and the Incentive Shares, on January 13, 2015, the Company and MD Anderson entered into a Registration Rights Agreement, or the Registration Rights Agreement, pursuant to which the Company agreed to file a “resale” registration statement, or the Registration Statement, registering the resale of the License Shares, the Incentive Shares and any other shares of the Company’s common stock held by MD Anderson on the date that the Registration Statement is filed Under the Registration Rights Agreement, the Company is obligated to maintain the effectiveness of the Registration Statement until all securities therein are sold or are otherwise can be sold pursuant to Rule 144, without any restrictions. A prospectus supplement under the Company’s already effective registration statement on Form S-3 (File No. 333-201826) was filed on April 1, 2015 in satisfaction of the Company’s obligations under the Registration Rights Agreement. The Company has determined that the rights acquired in the MD Anderson License represent in process research and development with no alternative future use. Accordingly, the Company recorded a charge of $67.3 million to research and development expense in 2015, representing the fair value of the 11,722,163 shares of its common stock on the date the MD Anderson License was executed. Ares Trading License and Collaboration Agreement On March 27, 2015, the Company and Intrexon signed a worldwide License and Collaboration Agreement, or the Ares Trading Agreement, with Ares Trading S.A., or Ares Trading, a subsidiary of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Under the collaboration, Ares Trading has elected two CAR + + Intrexon is entitled to receive $5.0 million payable in equal quarterly installments over two years for each identified product candidate, which will be used to fund discovery work. The Company will be responsible for costs exceeding the quarterly installments and all other costs of the preclinical research and development. Ares Trading paid a non-refundable upfront fee of $115.0 million to Intrexon as consideration for entry into the Ares Trading Agreement. Pursuant to the ECP Amendment, the Company was entitled to receive 50% of the upfront fee, or $57.5 million, which the Company received from Intrexon in July 2015. The Ares Trading Agreement provides for up to $413.0 million of potential payments for certain development and commercial milestones for each product candidate, and royalties ranging from the lower-single digits to the low-teens of net sales derived from the sale of products developed under agreement. The Ares Trading Agreement also provides for up to $50.0 million of payments upon the achievement of certain technical milestones. Intrexon will pay 50% of all milestone and royalty payments that it receives under the Ares Trading Agreement to the Company pursuant to the ECP Amendment. The term of the Ares Trading Agreement commenced in May 2015 and may be terminated by either party in the event of a material breach as defined in the agreement and may be terminated voluntarily by Ares Trading upon 90 days written notice to the Company. The Company considered FASB Accounting Standards Codification 605-25, Multiple-Element Arrangements Patent and Technology License Agreement—The University of Texas MD Anderson Cancer Center and the Texas A&M University System. On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin. The Company issued options to purchase 50,222 shares outside of the Company’s stock option plans following the successful completion of certain clinical milestones, of which 37,666 have vested. The remaining 12,556 shares vested upon enrollment of the first patient in a multi-center pivotal clinical trial i.e. a human clinical trial intended to provide the substantial evidence of efficacy necessary to support the filing of an approvable New Drug Application, or NDA. An expense of $87 thousand was charged to R&D expense for the vesting event which occurred in March 2016. This trial was initiated by Solasia Pharma K.K., or Solasia, on March 28, 2016 and triggered a $1.0 million milestone payment to the Company from Solasia which was received in May 2016. An equivalent milestone payment of $1.0 million was made to M.D. Anderson. In addition, the Licensors are entitled to receive certain milestone payments. The Company may be required to make additional payments upon achievement of certain other milestones in varying amounts which on a cumulative basis could total up to an additional $4.5 million. In addition, the Licensors are entitled to receive single digit percentage royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. Collaboration Agreement with Solasia Pharma K.K. On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia. Pursuant to the License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both IV and oral forms and related organic arsenic molecules, in all indications for human use in a pan- Asian/Pacific territory comprised of Japan, China, Hong Kong, Macau, Republic of Korea, Taiwan, Singapore, Australia, New Zealand, Malaysia, Indonesia, Philippines and Thailand. As consideration for the license, the Company received an upfront payment of $5.0 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific territory, and will be entitled to receive additional payments of up to $32.5 million in development-based milestones and up to $53.5 million in sales-based milestones. The Company will also be entitled to receive double digit royalty payments from Solasia based upon net sales of licensed products in the applicable territories, once commercialized, and a percentage of sublicense revenues generated by Solasia. The $5.0 million upfront payment received in March 2011 was amortized over the period of the Company’s research and development effort, which was completed in March 2016. On July 31, 2014, the Company entered into an amendment and restatement of the License and Collaboration Agreement granting Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. In exchange, the Company will be eligible to receive from Solasia development-and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company’s Licensors, as defined in the agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Company’s license agreement with the Licensors. On March 28, 2016, Solasia initiated a multi-center pivotal clinical trial intended to provide substantial evidence of efficacy necessary to support the filing of an application for an NDA for darinaparsin in certain of the territories assigned to Solasia. The initiation of the trial on March 28, 2016 triggered a $1.0 million milestone payment from Solasia to the Company which was received in May 2016. The Company subsequently made an equivalent payment to MD Anderson as the ultimate licensor of darinaparsin. License Agreement with Baxter Healthcare S.A. On November 3, 2006, the Company entered into a definitive Asset Purchase Agreement for indibulin and a License Agreement to proprietary nanosuspension technology with affiliates of Baxter Healthcare S.A. The purchase included the entire indibulin intellectual property portfolio as well as existing drug substance and capsule inventories. The terms of the Asset Purchase Agreement included an upfront cash payment and an additional payment for existing inventory. No payments were made during the six months ended June 30, 2016 and 2015. The Company is not actively pursuing the development of indibulin. |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Jun. 30, 2016 | |
Related Party Transactions | 6. Related Party Transactions Collaborations with Intrexon On January 6, 2011, the Company entered into the Channel Agreement with Intrexon (see Note 5). A director of the Company, Randal J. Kirk, is the CEO, a director, and the largest stockholder of Intrexon. On February 3, 2015, Intrexon purchased 1,440,000 shares of common stock in the Company’s public offering upon the same terms as others that participated in the offering. On March 27, 2015, the Company and Intrexon entered into a Second Amendment to Exclusive Channel Partner Agreement amending the Channel Agreement, which is referred to as the ECP Amendment. The ECP Amendment modified the scope of the parties’ collaboration under the Channel Agreement in connection with the worldwide License and Collaboration Agreement, or the Ares Trading Agreement, which the Company and Intrexon entered into with Ares Trading S.A., or Ares Trading, on March 27, 2015. The ECP Amendment provided that Intrexon will pay to the Company fifty percent of all payments that Intrexon receives for upfronts, milestones and royalties under the Ares Trading Agreement (see Note 5). The Amendment also reduces Intrexon’s aggregate commitment under a Stock Purchase Agreement that the parties executed in connection with the initial Channel Agreement to purchase the Company’s common stock from $50.0 million to $43.5 million, which has been satisfied. On June 29, 2015, the Company re-purchased 3,711 shares of common stock from Intrexon, at a discount of 5% to the closing price of the Company’s common stock on the date of purchase, which represented fractional shares that resulted from Intrexon’s special stock dividend of the Company’s shares to Intrexon’s shareholders, for $34 thousand. On January 8, 2016, the Company re-purchased an additional 168 shares of common stock from Intrexon for $2 thousand at the same terms as the previous share purchase. On September 28, 2015, the Company entered into the GvHD Agreement with Intrexon, whereby the Company will use Intrexon’s technology directed towards in vivo On June 29, 2016, the Company entered into a Third Amendment to Exclusive Channel Partner Agreement, or the 2016 ECP Amendment, with Intrexon, amending the Channel Agreement, and an Amendment to Exclusive Channel Collaboration Agreement, or the 2016 GvHD Amendment, amending their existing Exclusive Channel Collaboration Agreement, effective September 28, 2015, which the Company refers to as the GvHD Agreement. The 2016 ECP Amendment reduced the royalty percentage that the Company will pay to Intrexon under the Channel Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of ZIOPHARM Products (as defined in the Channel Agreement), calculated on a ZIOPHARM Product-by-ZIOPHARM Product basis, subject to certain expense allocations and other offsets provided in the Channel Agreement. The 2016 GvHD Amendment reduced the royalty percentage that the Company will pay to Intrexon under the GvHD Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of Products (as defined in the GvHD Agreement), subject to certain expense allocations and other offsets provided in the GvHD Agreement. The reductions in the royalty percentages provided by the 2016 ECP Amendment and the 2016 GvHD Amendment do not apply to sublicensing revenue or royalties under the Channel Agreement and GvHD Agreement, nor do they apply to any royalties or other payments made with respect to sublicensing revenue from the Company’s existing collaboration with Merck Serono, the biopharmaceutical business of Merck KGaA. In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company agreed to issue to Intrexon 100,000 shares of its newly designated Series 1 Preferred Stock. Each share of the Company’s Series 1 Preferred Stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization, and certain other rights, preferences, privileges and obligations (see Note 8). During the six months ended June 30, 2016 the Company expensed $12.1 million for services performed by Intrexon, of which $4.3 million is included within current liabilities. During the six months ended June 30, 2015 the Company expensed $7.4 million for services performed by Intrexon, of which $5.6 million is included within current liabilities. Collaboration with Intrexon and MD Anderson On January 13, 2015, the Company, together with Intrexon, entered into a license agreement with MD Anderson, which is referred to as the MD Anderson License. Pursuant to the MD Anderson License, the Company and Intrexon hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR + |
Stock-Based Compensation
Stock-Based Compensation | 6 Months Ended |
Jun. 30, 2016 | |
Stock-Based Compensation | 7. Stock-Based Compensation The Company recognized stock-based compensation expense on all employee and non-employee awards as follows: For the three For the six months (in thousands) 2016 2015 2016 2015 Research and development $ 476 $ 316 $ 893 $ 610 General and administrative 1,590 3,169 3,182 3,967 Stock-based compensation expense $ 2,066 $ 3,485 $ 4,075 $ 4,577 The Company granted an aggregate of 116,000 and 136,000 stock options during the three and six months ended June 30, 2016 with a weighted-average grant date fair value of $5.91 and $5.62 per share, respectively. The Company granted an aggregate of 1,800 and 51,800 stock options during the three and six months ended June 30, 2015 with a weighted-average grant date fair value of $6.85 and $6.59 per share, respectively. For the three months ended June 30, 2016 and 2015, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions: For the three months ended 2016 2015 Risk-free interest rate 1.38 - 1.54% 1.69% Expected life in years 6 6 Expected volatility 80.70 - 80.81% 85.57% Expected dividend yield 0 0 Stock option activity under the Company’s stock option plan for the six months ended June 30, 2016 is as follows: (in thousands, except share and per share data) Number of Weighted- Weighted- Aggregate Outstanding, December 31, 2015 3,481,469 $ 4.96 Granted 136,000 8.13 Exercised (169,000 ) 4.81 Cancelled (10,366 ) 6.48 Outstanding, June 30, 2016 3,438,103 $ 5.08 6.75 $ 4,046 Vested and unvested expected to vest at June 30, 2016 3,353,760 $ 5.08 5.71 $ 3,947 Options exercisable, June 30, 2016 2,237,935 $ 5.08 5.71 $ 3,430 Options exercisable, December 31, 2015 2,120,834 $ 4.24 5.84 $ 8,622 Options available for future grant 2,642,596 At June 30, 2016, total unrecognized compensation costs related to unvested stock options outstanding amounted to $4.2 million. The cost is expected to be recognized over a weighted-average period of 1.54 years. A summary of the status of unvested restricted stock for the six months ended June 30, 2016 is as follows: Number of Weighted- Non-vested, December 31, 2015 1,586,388 $ 9.00 Granted — — Vested (350,000 ) 9.35 Cancelled — — Non-vested, June 30, 2016 1,236,388 $ 9.00 At June 30, 2016, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $9.4 million. The cost is expected to be recognized over a weighted-average period of 1.53 years. |
Preferred Stock
Preferred Stock | 6 Months Ended |
Jun. 30, 2016 | |
Preferred Stock | 8. Preferred Stock The Company has 30,000,000 shares of preferred stock authorized, of which, 250,000 shares are designated as Series 1. On June 29, 2016, the Company entered into the 2016 ECP Amendment and 2016 GvHD Amendment with Intrexon (see note 5). In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company agreed to issue to Intrexon 100,000 shares of its newly designated Series 1 preferred stock. Each share of the Company’s Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization. The Series 1 preferred stock has the following rights and preferences and certain other rights, preferences, privileges and obligations. Conversion All shares of Series 1 preferred stock shall automatically convert into shares of common stock upon the public announcement of the first approval in the United States of (i) a ZIOPHARM Product under the Channel Agreement, (ii) a Product under the GvHD Agreement or (iii) a Product under the Ares Trading Agreement, which the Company refer to as the Conversion Event Date. On the second business day following the Conversion Event Date, each of Series 1 preferred stock shall convert into a number of shares of common stock equal to the stated value of such Series 1 preferred stock, divided by the greater of (i) the volume weighted average closing price of common stock as reported by The Nasdaq Stock Market, LLC over the 20 trading days ending on the Conversion Event Date or (ii) $1.00 per share; however, without shareholder approval in accordance with the NASDAQ Listing Rules, the Company will not affect any conversion of the Series 1 preferred stock into shares of common stock in excess of 19.9% of the lesser of (i) the pre-transaction outstanding shares of common stock or (ii) the outstanding shares of common stock at the time of conversion. In addition, without shareholder approval in accordance with the NASDAQ Listing Rules, the Company will not affect any conversion of the Series 1 preferred stock into common stock to the extent that the number of shares of common stock issued in such conversion would constitute a change of control under the NASDAQ Listing Rules. Dividends A monthly dividend, payable in additional shares of Series 1 preferred stock, equal to $12.00 per share, per month divided by the stated value per share, or the PIK Dividend; provided, that if any shares of Series 1 preferred stock are not converted on the Conversion Event Date (discussed below), then the rate of the PIK Dividend on all remaining unconverted shares of Series 1 preferred stock shall automatically increase from $12.00 to $24.00 per share, per month. Liquidation Preference In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a change of control or sale, lease transfer or exclusive license of all or substantially all of the Company’s assets prior to the conversion of the Series 1 preferred stock into shares of common stock, then the Series 1 preferred stock will participate in the proceeds of the transaction on a pro rata basis along with common stock, treating the Series 1 preferred stock as if it had been converted into a number of shares of common stock equal to the aggregate stated value of the Series 1 preferred stock, divided by the volume weighted average closing price of common stock over the 20 trading days ending on the public announcement of such voluntary or involuntary liquidation, dissolution or winding up of the Company or change of control or sale, lease transfer or exclusive license of all or substantially all of the Company’s assets. Alternatively, the Company may redeem the Series 1 preferred stock at a redemption price equal to the pro rata amount that the Series 1 preferred stock would have received if it had been converted using the same formula. Voting Rights The Series 1 preferred stock does not have any voting rights except that the Company may not, without the consent of the holders of a majority of the outstanding shares of the Series 1 preferred stock, voting as a separate class, (i) amend, alter or repeal any provision of its Certificate of Incorporation in a manner that adversely affects the powers, preferences or rights of the Series 1 preferred stock in a manner that is more adverse than the effect on any other class or series of the Company’s capital stock; (ii) (A) create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of the Company’s capital stock unless the same ranks junior or pari passu to the Series 1 preferred stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends and rights of redemption, or (B) reclassify, alter or amend any existing security that is junior or pari passu to the Series 1 preferred stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Series 1 preferred in respect of any such right, preference or privilege; or (iii) enter into any transaction (or series of related transactions) the effect of which would adversely affect the holders of the Series 1 preferred stock in a manner that is more adverse than the effect on any other class or series of capital stock. As of June 30, 2016 the Company has recorded its commitment to issue the Series 1 preferred stock as a liability at its estimated fair value of $119.1 million, with a corresponding charge to research and development expense in the Statement of Operations. The Series 1 preferred stock shares were subsequently issued on July 1, 2016. The Company analyzed the features of the Series 1 preferred stock and determined that the conversion option and the Company’s right to redeem the shares at liquidation are embedded derivatives that will require bifurcation from the Series 1 preferred stock in accordance with FASB ASC 815, Derivatives and Hedging The fair value of the preferred stock was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change and that change could be material. Inputs to the models included the following: Risk-free interest rate 0.94 % Expected dividend rate 0 Expected volatility 68.40 % Preferred stock conversion limit - percentage of outstanding common stock 19.90 % Preferred conversion floor price $ 1.00 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2016 | |
Assets and Liabilities Measured at Fair Value on Recurring Basis | Assets and liabilities measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015 were as follows: ($ in thousands) Balance as Fair Value Measurements at Reporting Date Using Description Quoted Prices in Significant Significant Cash equivalents $ 106,074 $ 106,074 $ — $ — Series 1 preferred stock issuance obligation $ (119,045 ) $ — $ — $ (119,045 ) ($ in thousands) Balance as of Fair Value Measurements at Reporting Date Using Description Quoted Prices in Significant Significant Cash equivalents $ 137,405 $ 137,405 $ — $ — |
Net Loss per Share (Tables)
Net Loss per Share (Tables) | 6 Months Ended |
Jun. 30, 2016 | |
Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share | The Company’s potential dilutive shares, which include outstanding common stock options, unvested restricted stock and preferred stock, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potential shares of common stock at June 30, 2016 and 2015 consisted of the following: June 30, 2016 2015 Stock options 3,438,103 3,543,331 Unvested restricted common stock 1,236,388 1,123,517 4,674,491 4,666,848 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2016 | |
Stock-Based Compensation Expense on All Employee and Non-Employee Awards | The Company recognized stock-based compensation expense on all employee and non-employee awards as follows: For the three For the six months (in thousands) 2016 2015 2016 2015 Research and development $ 476 $ 316 $ 893 $ 610 General and administrative 1,590 3,169 3,182 3,967 Stock-based compensation expense $ 2,066 $ 3,485 $ 4,075 $ 4,577 |
Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model | For the three months ended June 30, 2016 and 2015, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions: For the three months ended 2016 2015 Risk-free interest rate 1.38 - 1.54% 1.69% Expected life in years 6 6 Expected volatility 80.70 - 80.81% 85.57% Expected dividend yield 0 0 |
Stock Option Activity Under Stock Option Plan | Stock option activity under the Company’s stock option plan for the six months ended June 30, 2016 is as follows: (in thousands, except share and per share data) Number of Weighted- Weighted- Aggregate Outstanding, December 31, 2015 3,481,469 $ 4.96 Granted 136,000 8.13 Exercised (169,000 ) 4.81 Cancelled (10,366 ) 6.48 Outstanding, June 30, 2016 3,438,103 $ 5.08 6.75 $ 4,046 Vested and unvested expected to vest at June 30, 2016 3,353,760 $ 5.08 5.71 $ 3,947 Options exercisable, June 30, 2016 2,237,935 $ 5.08 5.71 $ 3,430 Options exercisable, December 31, 2015 2,120,834 $ 4.24 5.84 $ 8,622 Options available for future grant 2,642,596 |
Summary of Unvested Restricted Stock | A summary of the status of unvested restricted stock for the six months ended June 30, 2016 is as follows: Number of Weighted- Non-vested, December 31, 2015 1,586,388 $ 9.00 Granted — — Vested (350,000 ) 9.35 Cancelled — — Non-vested, June 30, 2016 1,236,388 $ 9.00 |
Preferred Stock (Tables)
Preferred Stock (Tables) | 6 Months Ended |
Jun. 30, 2016 | |
Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model | The fair value of the preferred stock was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change and that change could be material. Inputs to the models included the following: Risk-free interest rate 0.94 % Expected dividend rate 0 Expected volatility 68.40 % Preferred stock conversion limit - percentage of outstanding common stock 19.90 % Preferred conversion floor price $ 1.00 |
Business - Additional Informati
Business - Additional Information (Detail) - USD ($) $ in Thousands | Jun. 30, 2016 | Dec. 31, 2015 |
Nature Of Operations [Line Items] | ||
Accumulated deficit | $ 635,919 | $ 492,700 |
Assets and Liabilities Measured
Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands | Jun. 30, 2016 | Dec. 31, 2015 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | $ 106,074 | $ 137,405 |
Series 1 preferred stock issuance obligation | (119,045) | |
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash equivalents | 106,074 | $ 137,405 |
Significant Unobservable Inputs (Level 3) | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Series 1 preferred stock issuance obligation | $ (119,045) |
Potential Dilutive Shares Exclu
Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares | 6 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount | 4,674,491 | 4,666,848 |
Stock Options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount | 3,438,103 | 3,543,331 |
Restricted Stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount | 1,236,388 | 1,123,517 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) | Jun. 29, 2016$ / sharesshares | Sep. 28, 2015USD ($) | May 22, 2015USD ($) | Mar. 31, 2015USD ($) | Jan. 13, 2015USD ($)shares | Jan. 09, 2015USD ($)shares | Mar. 07, 2011USD ($) | Jan. 06, 2011 | Aug. 24, 2004Patent | Jul. 31, 2015USD ($) | Jun. 30, 2016USD ($)$ / shares | Jun. 30, 2015USD ($) | Jun. 30, 2016USD ($)$ / sharesshares | Jun. 30, 2015USD ($) | Dec. 31, 2015USD ($)$ / sharesshares | Dec. 31, 2013USD ($) | Dec. 31, 2012 | Dec. 31, 2011USD ($) | Mar. 31, 2016USD ($) | May 31, 2015USD ($) | Dec. 31, 2014USD ($)shares |
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Loss on disposal of fixed assets | $ 1,000 | ||||||||||||||||||||
Total rent Expense | $ 122,000 | 477,000 | |||||||||||||||||||
Deferred rent - current portion | $ 223,000 | 223,000 | $ 348,000 | ||||||||||||||||||
Deferred rent-non-current portion | 200,000 | 200,000 | 313,000 | ||||||||||||||||||
Deferred rent liability net | 423,000 | 423,000 | $ 661,000 | ||||||||||||||||||
Research and Development Expense | $ 129,228,000 | $ 7,424,000 | $ 139,427,000 | 81,673,000 | |||||||||||||||||
Preferred stock, stated value | $ / shares | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||||||||||||
Research and development arrangement Terms | Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15 million and no greater than $20 million per year. | ||||||||||||||||||||
Research and Development Service Agreement Aggregate Quarterly Payments | $ 3,800,000 | ||||||||||||||||||||
Offset costs in research and development expense | 1,700,000 | ||||||||||||||||||||
Research and Development Service Agreement Aggregate Payments | 18,800,000 | ||||||||||||||||||||
Deferred revenue - current portion | $ 6,389,000 | 6,389,000 | $ 6,861,000 | ||||||||||||||||||
Deferred Revenue, long term | 44,722,000 | $ 44,722,000 | 47,917,000 | ||||||||||||||||||
Issuance of common stock in a license agreement | 67,285,000 | ||||||||||||||||||||
The University of Texas MD Anderson Cancer Center and The Texas A & M University System | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Milestone maximum payment | $ 4,500,000 | ||||||||||||||||||||
Number of products | Patent | 2 | ||||||||||||||||||||
Options to purchase common stock | shares | 50,222 | ||||||||||||||||||||
Shares vested | shares | 37,666 | ||||||||||||||||||||
The University of Texas MD Anderson Cancer Center and The Texas A & M University System | Research and Development Expense | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Issuance of common stock in a license agreement | $ 87,000 | ||||||||||||||||||||
The University of Texas MD Anderson Cancer Center and The Texas A & M University System | Upon enrollment of the first patient in a multi-center pivotal clinical trial | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Shares vested | shares | 12,556 | ||||||||||||||||||||
Solasia | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Upfront payment received | $ 5,000,000 | ||||||||||||||||||||
Milestone payment received | $ 1,000,000 | ||||||||||||||||||||
Milestone Payments Payable | $ 1,000,000 | ||||||||||||||||||||
Solasia | Development-based milestones | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Expected Additional milestone payments to be received | 32,500,000 | ||||||||||||||||||||
Solasia | Sales-based milestones | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Expected Additional milestone payments to be received | 53,500,000 | ||||||||||||||||||||
Baxter Healthcare Corporation | Upon the successful U.S. IND application for indibulin | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Installment payments | 0 | $ 0 | |||||||||||||||||||
License Agreement | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Research and Development Expense | $ 67,300,000 | $ 67,300,000 | |||||||||||||||||||
Issuance of common stock in licensing agreement, shares | shares | 11,722,163 | 11,722,163 | |||||||||||||||||||
ARES Trading License | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Agreement termination, notice period | 90 days | ||||||||||||||||||||
Payments for development and commercial milestones per Product | $ 413,000,000 | ||||||||||||||||||||
Milestone payments, percentage | 50.00% | ||||||||||||||||||||
Agreement commencement date | 2015-05 | ||||||||||||||||||||
Deferred revenue, revenue recognized | 1,600,000 | $ 3,200,000 | |||||||||||||||||||
Deferred revenue, upfront payment | 51,100,000 | 51,100,000 | $ 57,500,000 | ||||||||||||||||||
Deferred revenue - current portion | 6,400,000 | 6,400,000 | |||||||||||||||||||
Minimum | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Research and Development Expense | $ 15,000,000 | ||||||||||||||||||||
Maximum | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Research and Development Expense | 20,000,000 | ||||||||||||||||||||
Prepaid Expenses and Other Current Assets | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Pre paid research and development expenses | 17,100,000 | $ 17,100,000 | |||||||||||||||||||
Intrexon Corporation | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Contract termination description | The Company's obligation to pay 50% of net profits (now 20% of net profits after the amendment pursuant to the 2016 ECP Amendment, discussed below) or revenue described above with respect to these "retained" products will survive termination of the Channel Agreement. | ||||||||||||||||||||
Licensing fee | $ 10,000,000 | $ 115,000,000 | |||||||||||||||||||
Milestone payment receivable | $ 5,000,000 | ||||||||||||||||||||
Milestone payment receivable period | 2 years | ||||||||||||||||||||
Upfront payment received | $ 57,500,000 | ||||||||||||||||||||
Percentage of upfront fee Payable | 50.00% | ||||||||||||||||||||
Milestone maximum payment | 50,000,000 | $ 50,000,000 | |||||||||||||||||||
Intrexon Corporation | 2016 GvHD Amendment | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Royalty percentage of net profit | 50.00% | ||||||||||||||||||||
Contract termination description | The Company's obligation to pay 50% of net profits or revenue with respect to these "retained" products will survive termination of the GvHD Agreement. | ||||||||||||||||||||
Licensing fee | $ 10,000,000 | ||||||||||||||||||||
Research and Development Expense | $ 10,000,000 | ||||||||||||||||||||
Agreement termination period | 24 months | ||||||||||||||||||||
Agreement termination, notice period | 90 days | ||||||||||||||||||||
Intrexon Corporation | License Agreement | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Cash consideration for license agreement | $ 50,000,000 | ||||||||||||||||||||
Intrexon Corporation | Letter Agreement | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Cash consideration for license agreement | $ 7,500,000 | ||||||||||||||||||||
Intrexon Corporation | Quarterly Payment | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Royalty percentage of net profit | 50.00% | ||||||||||||||||||||
Percentage of revenue agreed to pay which is obtained from sublicensor | 50.00% | ||||||||||||||||||||
Intrexon Corporation | Quarterly Payment | 2016 GvHD Amendment | Before Amendment | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Royalty percentage of net profit | 50.00% | ||||||||||||||||||||
Intrexon Corporation | Quarterly Payment | 2016 GvHD Amendment | 2016 GvHD Amendment | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Royalty percentage of net profit | 20.00% | ||||||||||||||||||||
Intrexon Corporation | Quarterly Payment | ECP Channel Agreement | 2016 ECP Amendment | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Royalty percentage of net profit | 20.00% | ||||||||||||||||||||
Intrexon Corporation | Quarterly Payment | ECP Channel Agreement | Before Amendment | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Royalty percentage of net profit | 50.00% | ||||||||||||||||||||
Intrexon Corporation | Series 1 Preferred Stock | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Stock reserved for future issuance | shares | 100,000 | ||||||||||||||||||||
Preferred stock, stated value | $ / shares | $ 1,200 | ||||||||||||||||||||
ZIOPHARM | License Agreement | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Common stock issued for cash | shares | 10,124,561 | ||||||||||||||||||||
Cash consideration for license agreement | $ 50,000,000 | ||||||||||||||||||||
ZIOPHARM | Letter Agreement | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Common stock issued for cash | shares | 1,597,602 | ||||||||||||||||||||
Cash consideration for license agreement | $ 7,500,000 | ||||||||||||||||||||
Boston, MA | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Operating lease expiration month and year | 2016-08 | 2016-08 | |||||||||||||||||||
Loss on sublease | $ 42,000 | ||||||||||||||||||||
Remaining contractual obligation | 367,000 | ||||||||||||||||||||
Sublease revenue from subtenant | $ 105,000 | 325,000 | |||||||||||||||||||
Security deposits | $ 17,000 | 128,000 | $ 128,000 | $ 128,000 | |||||||||||||||||
Sublease term amendment | Aug. 31, 2021 | ||||||||||||||||||||
Security deposit from subtenant | $ 20,000 | ||||||||||||||||||||
Boston, MA | The first floor | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Loss on sublease | $ 167,000 | ||||||||||||||||||||
New York, NY | |||||||||||||||||||||
Commitments and Contingencies Disclosure [Line Items] | |||||||||||||||||||||
Letter of credit | $ 388,000 | $ 388,000 | $ 388,000 | ||||||||||||||||||
Operating lease expiration month and year | 2018-10 | ||||||||||||||||||||
Loss on sublease | 729,000 | ||||||||||||||||||||
Remaining contractual obligation | 2,300,000 | ||||||||||||||||||||
Sublease revenue from subtenant | 1,600,000 | ||||||||||||||||||||
Loss on disposal of fixed assets | $ (392,000) |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | Jun. 29, 2016 | Jan. 08, 2016 | Sep. 28, 2015 | Jun. 29, 2015 | Mar. 27, 2015 | Feb. 03, 2015 | Jan. 06, 2011 | Jul. 31, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | Dec. 31, 2015 |
Related Party Transaction [Line Items] | |||||||||||||
Commitment to purchase common stock | $ 2 | $ 34 | |||||||||||
Stock buy back | $ 2 | ||||||||||||
Preferred stock, stated value | $ 0.001 | $ 0.001 | $ 0.001 | ||||||||||
Research and Development Expense | $ 129,228 | $ 7,424 | $ 139,427 | 81,673 | |||||||||
Research and Development Service Agreement Aggregate Quarterly Payments | 3,800 | ||||||||||||
Research and Development Service Agreement Aggregate Payments | 18,800 | ||||||||||||
License Agreement | |||||||||||||
Related Party Transaction [Line Items] | |||||||||||||
Research and Development Expense | $ 67,300 | $ 67,300 | |||||||||||
Issuance of common stock in licensing agreement (in shares) | 11,722,163 | 11,722,163 | |||||||||||
Intrexon Corporation | |||||||||||||
Related Party Transaction [Line Items] | |||||||||||||
Stock issued during period | 1,440,000 | ||||||||||||
Commitment to purchase common stock | $ 43,500 | $ 50,000 | |||||||||||
Percentage of commitment for payments from receipts of upfronts, milestones and royalties | 50.00% | ||||||||||||
Stock buy back (Shares) | 3,711 | ||||||||||||
Stock buy back | $ 34 | ||||||||||||
Share buy back discount on closing price | 5.00% | ||||||||||||
Company re-purchased additional shares | 168 | ||||||||||||
Company re-purchased additional shares Value | $ 2 | ||||||||||||
Licensing fee | $ 10,000 | $ 115,000 | |||||||||||
Amounts expensed for services incurred | $ 12,100 | 7,400 | |||||||||||
Amount due to related party, current | $ 4,300 | $ 5,600 | $ 4,300 | $ 5,600 | |||||||||
Intrexon Corporation | Series 1 Preferred Stock | |||||||||||||
Related Party Transaction [Line Items] | |||||||||||||
Stock reserved for future issuance | 100,000 | ||||||||||||
Preferred stock, stated value | $ 1,200 | ||||||||||||
Intrexon Corporation | 2016 GvHD Amendment | |||||||||||||
Related Party Transaction [Line Items] | |||||||||||||
Licensing fee | $ 10,000 | ||||||||||||
Royalty percentage of net profit | 50.00% | ||||||||||||
Research and Development Expense | $ 10,000 | ||||||||||||
Intrexon Corporation | Quarterly Payment | |||||||||||||
Related Party Transaction [Line Items] | |||||||||||||
Royalty percentage of net profit | 50.00% | ||||||||||||
Intrexon Corporation | Quarterly Payment | ECP Channel Agreement | 2016 ECP Amendment | |||||||||||||
Related Party Transaction [Line Items] | |||||||||||||
Royalty percentage of net profit | 20.00% | ||||||||||||
Intrexon Corporation | Quarterly Payment | ECP Channel Agreement | Before Amendment | |||||||||||||
Related Party Transaction [Line Items] | |||||||||||||
Royalty percentage of net profit | 50.00% | ||||||||||||
Intrexon Corporation | Quarterly Payment | 2016 GvHD Amendment | Before Amendment | |||||||||||||
Related Party Transaction [Line Items] | |||||||||||||
Royalty percentage of net profit | 50.00% | ||||||||||||
Intrexon Corporation | Quarterly Payment | 2016 GvHD Amendment | 2016 GvHD Amendment | |||||||||||||
Related Party Transaction [Line Items] | |||||||||||||
Royalty percentage of net profit | 20.00% |
Stock-Based Compensation Expens
Stock-Based Compensation Expense Included in Statement of Operations (Detail) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock-based compensation | $ 2,066 | $ 3,485 | $ 4,075 | $ 4,577 |
Research and Development Expense | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock-based compensation | 476 | 316 | 893 | 610 |
General and Administrative Expense | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock-based compensation | $ 1,590 | $ 3,169 | $ 3,182 | $ 3,967 |
Stock-Based Compensation - Addi
Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options, granted | 116,000 | 1,800 | 136,000 | 51,800 |
Weighted-average grant date fair value | $ 5.91 | $ 6.85 | $ 5.62 | $ 6.59 |
Unvested Stock | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Unrecognized compensation costs related to unvested restricted stock outstanding | $ 4.2 | $ 4.2 | ||
Expected recognition period | 1 year 6 months 15 days | |||
Unvested Restricted Common Stock | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Expected recognition period | 1 year 6 months 11 days | |||
Unrecognized stock-based compensation expense related to unvested restricted stock | $ 9.4 | $ 9.4 |
Fair Value of Stock Options Ass
Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail) | 3 Months Ended | |
Jun. 30, 2016 | Jun. 30, 2015 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Risk-free interest rate, Minimum | 1.38% | |
Risk-free interest rate, Maximum | 1.54% | |
Risk-free interest rate | 1.69% | |
Expected life in years | 6 years | 6 years |
Expected volatility, Minimum | 80.70% | |
Expected volatility, Maximum | 80.81% | |
Expected volatility | 85.57% | |
Expected dividend yield | 0.00% | 0.00% |
Stock Option Activity Under Sto
Stock Option Activity Under Stock Option Plan (Detail) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2016 | Jun. 30, 2015 | Jun. 30, 2016 | Jun. 30, 2015 | Dec. 31, 2015 | |
Number of Shares | |||||
Beginning Balance | 3,481,469 | ||||
Granted | 116,000 | 1,800 | 136,000 | 51,800 | |
Exercised | (169,000) | ||||
Cancelled | (10,366) | ||||
Ending Balance | 3,438,103 | 3,438,103 | 3,481,469 | ||
Vested and unvested expected to vest at end of period | 3,353,760 | 3,353,760 | |||
Options exercisable, at end of period | 2,237,935 | 2,237,935 | 2,120,834 | ||
Options available for future grant | 2,642,596 | 2,642,596 | |||
Weighted Average Exercise Price | |||||
Beginning Balance | $ 4.96 | ||||
Granted | 8.13 | ||||
Exercised | 4.81 | ||||
Cancelled | 6.48 | ||||
Ending Balance | $ 5.08 | 5.08 | $ 4.96 | ||
Vested and unvested expected to vest at end of period | 5.08 | 5.08 | |||
Options exercisable, at end of period | $ 5.08 | $ 5.08 | $ 4.24 | ||
Weighted Average Contractual Term (Years) | |||||
Outstanding, at end of period | 6 years 9 months | ||||
Vested and unvested expected to vest at end of period | 5 years 8 months 16 days | ||||
Options exercisable, at end of period | 5 years 8 months 16 days | 5 years 10 months 2 days | |||
Aggregate Intrinsic Value | |||||
Outstanding, at end of period | $ 4,046 | $ 4,046 | |||
Vested and unvested expected to vest at end of period | 3,947 | 3,947 | |||
Options exercisable, at end of period | $ 3,430 | $ 3,430 | $ 8,622 |
Summary of Unvested Restricted
Summary of Unvested Restricted Stock (Detail) - Unvested Restricted Common Stock | 6 Months Ended |
Jun. 30, 2016$ / sharesshares | |
Number of Shares | |
Beginning Balance | shares | 1,586,388 |
Granted | shares | 0 |
Vested | shares | (350,000) |
Cancelled | shares | 0 |
Ending Balance | shares | 1,236,388 |
Weighted Average Grant Date Fair Value | |
Beginning Balance | $ / shares | $ 9 |
Granted | $ / shares | 0 |
Vested | $ / shares | 9.35 |
Cancelled | $ / shares | 0 |
Ending Balance | $ / shares | $ 9 |
Preferred Stock - Additional In
Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands | 6 Months Ended | |||
Jun. 30, 2016 | Jul. 01, 2016 | Jun. 29, 2016 | Dec. 31, 2015 | |
Preferred Stock [Line Items] | ||||
Preferred stock, shares authorized | 30,000,000 | 30,000,000 | ||
Preferred stock, stated value | $ 0.001 | $ 0.001 | ||
Series 1 Preferred Stock | ||||
Preferred Stock [Line Items] | ||||
Preferred stock, shares authorized | 250,000 | 250,000 | ||
Maximum percentage of common stock issuable upon conversion of preferred stock | 19.90% | |||
Intrexon Corporation | ||||
Preferred Stock [Line Items] | ||||
Series 1 preferred stock issuance obligation | $ 119,045 | |||
Embedded conversion liability | $ 700 | |||
Intrexon Corporation | Subsequent Event | ||||
Preferred Stock [Line Items] | ||||
fair value of Series 1 preferred stock will reclassify as a component of temporary equity | $ 118,400 | |||
Intrexon Corporation | Series 1 Preferred Stock | ||||
Preferred Stock [Line Items] | ||||
Stock reserved for future issuance | 100,000 | |||
Preferred stock, stated value | $ 1,200 | |||
Preferred stock, conversion rate | $ 1 | |||
Maximum percentage of common stock issuable upon conversion of preferred stock | 19.90% | |||
Intrexon Corporation | Series 1 Preferred Stock | Before Conversion Event Date | ||||
Preferred Stock [Line Items] | ||||
Preferred stock monthly dividend payable (per share) | $ 12 | |||
Intrexon Corporation | Series 1 Preferred Stock | Remaining Unconverted Shares | ||||
Preferred Stock [Line Items] | ||||
Preferred stock monthly dividend payable (per share) | $ 24 |
Fair Value Assumptions Used in
Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model (Detail) - Series 1 Preferred Stock | 6 Months Ended |
Jun. 30, 2016$ / shares | |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] | |
Risk-free interest rate | 0.94% |
Expected dividend rate | 0.00% |
Expected volatility | 68.40% |
Preferred stock conversion limit - percentage of outstanding common stock | 19.90% |
Preferred conversion floor price | $ 1 |